Discontinued — last reported Q1 '18
Lam Research Allowance for Doubtful Accounts Receivable (Current) increased by 8.2% to $8.35M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 41.8%, from $5.89M to $8.35M. Over 4 years (FY 2021 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 5.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.26M | $5.36M | $5.38M | $5.60M | $5.61M | $5.54M | $5.41M | $5.36M | $5.34M | $5.26M | $5.32M | $5.29M | $5.28M | $5.58M | $5.71M | $5.89M | $6.50M | $6.54M | $7.72M | $8.35M |
| QoQ Change | — | +2.0% | +0.3% | +4.1% | +0.1% | -1.2% | -2.3% | -1.0% | -0.3% | -1.7% | +1.3% | -0.7% | -0.2% | +5.7% | +2.4% | +3.0% | +10.4% | +0.7% | +18.0% | +8.2% |
| YoY Change | — | — | — | — | +6.7% | +3.3% | +0.6% | -4.3% | -4.7% | -5.1% | -1.6% | -1.4% | -1.3% | +6.2% | +7.3% | +11.4% | +23.1% | +17.2% | +35.1% | +41.8% |